Prescribing of FDA-approved and compounded hormone therapy differs by specialty

Constantine, Ginger D.; Archer, David F.; Graham, Shelli; Bernick, Brian; Mirkin, Sebastián

doi:10.1097/gme.0000000000000683

Cited by 13 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of physicians who completed the survey could also be a limitation; while the number of completed surveys was not very high (27%), it was also not particularly low when compared with the completion rates other surveys (10%–41%) in the published medical literature. 18,21,22,24 In addition, the demographics of the respondents were fairly similar to the data of the 2016 Physician Specialty Data Report, which reported that males account for 46% of OB/GYNs and 62% of family medicine/general practice physicians in the United States, with the majority (56% and 58%, respectively) being under the age of 55. 51 Physicians who completed the survey also received an incentive, which could have affected how they answered the questions.…”

Section: Discussionsupporting

confidence: 67%

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history

Kingsberg

Larkin²,

Krychman

et al. 2019

Menopause

Self Cite

View full text Add to dashboard Cite

More OB/GYNs than PCPs prescribed VVA treatment, especially vaginal estrogens, for menopausal women, but both groups generally had similar attitudes and behaviors regarding VVA treatment. Physician comfort was low when prescribing to women with a history of breast cancer, despite women's health medical societies supporting vaginal estrogen use in women with a history of estrogen-dependent breast cancer who were unresponsive to nonhormonal therapies when offered in consultation with their oncologist.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0.

show abstract

Section: Discussionsupporting

confidence: 67%

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history

Kingsberg

Larkin²,

Krychman

et al. 2019

Menopause

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,2 The prevalence of GSM is reported to be as high as 50% to 70% [3][4][5][6][7] in postmenopausal women; however, according to a 2013 study, only 7% of affected women are being treated with prescription therapy. 2 Although previous surveys on the management and treatment for GSM have been undertaken in physician groups, [8][9][10] as well as separately evaluating nurse practitioners, 11 no surveys to date have examined differences in the evaluation and management of patients exhibiting GSM among healthcare providers (HCPs) in different specialties and training levels. Furthermore, HCPs in the Greater Memphis Area treat patients with high incidence rates of many comorbidities that serve as risk factors for GSM such as lack of exercise, 12 low education levels, 13 and morbid obesity.…”

mentioning

confidence: 99%

Healthcare provider knowledge, attitudes, and preferences in management of genitourinary syndrome of menopause in the Mid-South

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Menopausal hormonal therapy (MHT) ameliorates vasomotor symptomatology, prevents bone loss, and treats estrogen deficiency-related genitourinary symptoms [1]. As such, it is an FDA-approved therapy for these symptoms [1,2]. Whether MHT confers harmful or beneficial effects on cardiovascular (CV) system is controversial.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular Risk/Benefit Profile of MHT

et al. 2019

View full text Add to dashboard Cite

Background and Objectives: Data emerging from the Women’s Health Initiative (WHI) study point toward an association between menopausal hormone therapy (MHT) and cardiovascular (CV) risk. However, post hoc subgroup analyses stratifying participants according to their age and time since menopause, have opened the way to a better understanding of the relationship between estrogen and CV risk. The aim of this review was to revise the current literature and evaluate the CV risk or benefit following administration of MHT considering several factors such as MHT timing, dose, route of administration, and formulation. Materials and Methods: An electronic databases search of MEDLINE (PubMed), Cochrane Central Register of Controlled Trials, Web of Science, SCOPUS, congress abstracts, and Grey literature (Google Scholar; British Library) was performed, with the date range from each database’s inception until June 2019. All the studies evaluating MHT and cardiovascular risk, including thromboembolism or stroke, were selected. Results: Timing of MHT initiation was shown to be a critical factor in CV risk assessment. In concordance with the “timing hypothesis”, healthy symptomatic women who initiated MHT when aged younger than 60 years, or who were within 10 years of menopause onset, have demonstrated a reduction in both coronary heart disease (CHD) risk and all-cause mortality. In particular, MHT therapy was associated with improvement of subclinical signs of atherosclerosis. Venous thromboembolism (VTE) risk is reduced when low doses of oral estrogen are used. Moreover, transdermal hormonal application significantly reduces CV risk compared with oral administration. MHT impact on the CV system is influenced by either factors inherent to the specific regimen, or factors inherent to the specific patient. Hence, individualization of care is necessary. Conclusion: CV risk calculation should be considered by clinicians in order to exclude patients with high CV risk, in whom MHT is contraindicated. Assessing risks and benefits in a patient-centered approach according to individual’s features, health status, and personal preferences is important in order to realize a safe and effective treatment.

show abstract

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

Abstract: Supplemental Digital Content is available in the text

Cited by 13 publications

References 23 publications

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history

Healthcare provider knowledge, attitudes, and preferences in management of genitourinary syndrome of menopause in the Mid-South

Cardiovascular Risk/Benefit Profile of MHT

Contact Info

Product

Resources

About